Physician profile
Robert J Segal
NPI 1306823216
$2,041.51
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,667 · 2020: $238 · 2021: $71.53 · 2022: $64.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $386.22 | 2019 | |
| Biofrontera INC. | $370.16 | 2019 | |
| Abbvie INC. | $245.30 | 2019-2022 | |
| Janssen Biotech, INC. | $192.27 | 2019 | |
| Genentech USA, INC. | $161.48 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $145.44 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $114.27 | 2019 | |
| Leo Pharma INC. | $75.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.46 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $70.74 | 2019-2020 | |
| Pfizer INC. | $67.32 | 2019-2020 | |
| Ucb, INC. | $47.01 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $44.93 | 2019 | |
| Allergan, INC. | $24.48 | 2020 | |
| Lilly USA, LLC | $15.27 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $9.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Segal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.